Effects of 17 months treatment using recombinant insulin‐like growth factor‐I in two children with growth hormone insensitivity (Laron) syndrome

Abstract

Treatment of two patients with growth hormone insensitivity syndrome using 40 micrograms/kg of IGF-I twice a day resulted in increased linear bone growth and bone mineralization as well as increased bone maturation without remarkable adverse events. After 1 year of therapy, growth response could no longer be observed in these two patients.